Table 1D.
Islet product characteristics
| Total (n = 1017) | Era | p-Value | |||
|---|---|---|---|---|---|
| 1999–2002 (n = 257) | 2003–2006 (n = 472) | 2007–2010 (n = 288) | |||
| Islet mass | |||||
| Total IEQs (×103) at time of particle count | 416 ± 156.9 (n = 773) | 417.5 ± 160.6 | 413.7 ± 159.9 | 419.2 ± 146.7 | |
| IEQ/islet particle ratio | 1.1 ± 0.6 (n = 655) | 1.1 ± 0.5 | 1.1 ± 0.4 | 1.3 ± 0.8 | <0.001 |
| IEQs infused (×103) | 426.5 ± 157.1 (n = 1015) | 421.3 ± 155.4 | 417.8 ± 157.6 | 445.4 ± 156.8 | <0.05 |
| Packed cell volume infused (mL) | 3.9 ± 2.2 (n = 825) | 4.1 ± 2.1 | 3.9 ± 2 | 3.8 ± 2.8 | |
| Islet quality | |||||
| Purity (%) | 61.8 ± 18.3 (n = 770) | 59 ± 19.1 | 61.7 ± 18.5 | 65.1 ± 16.4 | <0.01 |
| Embedded islets (%) | 15.7 ± 18.7 (n = 527) | 13.6 ± 17.7 | 16.1 ± 19.5 | 16.9 ± 18 | |
| Stimulation index | 3.3 ± 3.3 (n = 693) | 3.8 ± 3.9 | 3.2 ± 3.2 | 2.7 ± 2.7 | <0.001 |
| Islet viability (%) | 91.2 ± 6.2 (n = 752) | 91.4 ± 6.9 | 91.5 ± 6 | 90.2 ± 5.9 | <0.01 |
| Total beta cells (×106) | 231.1 ± 191.5 (n = 228) | 196.2 ± 180 | 235.6 ± 191.9 | 318.9 ± 201.4 | <0.05 |
| Total beta cells (×106)/kg recipient | 3.6 ± 3.1 (n = 219) | 3 ± 2.8 | 3.8 ± 3.2 | 4.5 ± 2.8 | |
| Total insulin content of islets (mg) | 3.5 ± 2.2 (n = 247) | 3.2 ± 2 | 3.6 ± 2.4 | 1.7 ± 0.5 | |
| Total endotoxin infused (EU) | 22.7 ± 54.9 (n = 667) | 29.4 ± 60.7 | 26.1 ± 60 | 7.8 ± 26.7 | |
| Total endotoxin (EU)/kg recipient | 0.4 ± 0.8 (n = 651) | 0.5 ± 1 | 0.4 ± 0.9 | 0.1 ± 0.5 | |
IEQ, islet equivalent.